ANNAPOLIS, MD — In a poignant and detailed update to the metastatic breast cancer (MBC) community, Dr. Kelly Shanahan, President of METAvivor, has shared a personal health update that underscores the volatile nature of Stage IV cancer while simultaneously announcing a suite of new advocacy, education, and fundraising initiatives. Dr. Shanahan, a physician who has been living with MBC for several years, revealed that her own treatment path has recently shifted due to tumor evolution—a common but challenging hurdle in the management of metastatic disease.
As the organization prepares for its most active season, including the "Stage IV Stampede" and the "Light Up MBC" global campaign, Dr. Shanahan’s dual perspective as both a medical professional and a patient provides a unique lens into the current state of MBC research and the urgent need for biomarker-driven personalized medicine.
Main Facts: A Dual Battle for Health and Research Funding
The primary focus of METAvivor’s late-summer briefing is the intersection of personal patient experience and systemic advocacy. Dr. Shanahan reported that after a period of stability, her clinical trial treatment failed to control the spread of her disease. This progression was marked by a significant biological shift: her cancer, which was previously highly Estrogen Receptor (ER) and Progesterone Receptor (PR) positive, has mutated to become "ER/PR low" and "HER2-low."
This phenomenon, known as "tumor heterogeneity" or "clonal evolution," is a primary reason why metastatic breast cancer remains a terminal diagnosis. When a tumor progresses, the new metastatic sites (in Dr. Shanahan’s case, the liver) may possess different genetic and proteomic profiles than the original tumor. This necessitates a change in strategy, moving Dr. Shanahan from trial-based therapy to a combination of immunotherapy and the oral chemotherapy capecitabine (Xeloda).
Beyond the personal, METAvivor is launching several high-impact programs:
- The Biomarker Education Program: A comprehensive initiative designed to help patients understand the genetic "signatures" of their tumors.
- Stage IV Stampede and Hill Day: A grassroots lobbying effort in Washington, D.C., scheduled for early October.
- Partnership with "Live from Stage 4": A new media collaboration to bring researcher interviews and breakthrough discussions to a wider audience.
- The R.I.S.E Initiative: Standing for Reach, Inform, Support, and Empower, this program aims to bolster peer-to-peer support networks.
Chronology: From Summer Setbacks to Fall Advocacy
The timeline of Dr. Shanahan’s recent experience reflects the rapid pace at which life with MBC can change.
Early Summer 2024: Dr. Shanahan dealt with a physical setback—a broken foot—which limited her mobility. During this time, she remained on a clinical trial drug that initially showed promise in treating her MBC.
Mid-Summer 2024: Routine monitoring and a "mixed response" on scans indicated that while some "spots" were responding to the trial drug, others were not. Crucially, new metastatic lesions appeared in her liver. This prompted a diagnostic pivot. Dr. Shanahan underwent liquid biopsies (blood tests that detect circulating tumor DNA) which revealed a high Tumor Mutational Burden (TMB) and a shift in her hormone receptor status.
Late August 2024: Following consultations with her "village of oncologists," Dr. Shanahan began a new regimen of immunotherapy and oral chemotherapy. Early clinical signs, such as the resolution of numbness in a specific metastatic area, suggest the new treatment may be effective. Confirmatory scans are scheduled for late August.
October 5–6, 2024: METAvivor will host the Stage IV Stampede and Summit. This event serves as a briefing for advocates before they head to Capitol Hill on October 6 to meet with legislators.
October 13, 2024: The organization will hold its largest annual fundraiser, "Light Up MBC." This global event illuminates landmarks in green, teal, and pink to represent the unique colors of metastatic breast cancer awareness.
Supporting Data: The Science of Biomarkers and MBC Progression
The challenges Dr. Shanahan faces are reflected in broader oncology statistics. Metastatic breast cancer accounts for approximately 685,000 deaths annually worldwide. While early-stage breast cancer has seen a survival rate increase, the median survival for Stage IV remains approximately three years, though many patients, like Dr. Shanahan, live much longer due to advances in targeted therapy.
The Importance of Biomarkers
A "biomarker" is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. In MBC, biomarkers like ER, PR, HER2, and PIK3CA determine which drugs will be effective.
Data suggests that up to 40% of patients may experience a change in their receptor status (e.g., from ER-positive to ER-negative) when the cancer spreads to a new organ. Dr. Shanahan’s transition to "HER2-low" is particularly significant. Until recently, patients were classified as either HER2-positive or HER2-negative. The "HER2-low" designation is a new clinical category that opens the door to specific antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (Enhertu), which have revolutionized treatment for this subset of patients.
Liquid Biopsy vs. Tissue Biopsy
Dr. Shanahan emphasized the necessity of liquid biopsies. While a traditional tissue biopsy remains the "gold standard," it can be invasive and difficult to perform on certain liver or bone lesions. Liquid biopsies detect "cell-free DNA" (cfDNA) shed by tumors into the bloodstream. This technology allows for real-time monitoring of mutations and "Tumor Mutational Burden," which helps predict how well a patient might respond to immunotherapy.
Official Responses and Organizational Vision
In her letter, Dr. Shanahan speaks not only as a patient but as a leader driving an organization that fills a critical gap in the cancer landscape. Historically, only 2-5% of breast cancer research funding has been dedicated to the metastatic stage, despite it being the only stage that kills.
"METAvivor exists for and because of you," Shanahan stated, addressing the patient community. She highlighted the organization’s unique grant review process, which includes "patient advocate reviewers." This ensures that the research being funded is not just scientifically sound but also "vital" and "meaningful" to those living with the disease.
The organization’s partnership with the Live from Stage 4 podcast represents a strategic move to democratize information. By featuring METAvivor-funded researchers, the podcast aims to bridge the gap between high-level laboratory science and the day-to-day realities of managing side effects and treatment fatigue.
Tami Bowling, lead for the "Light Up MBC" campaign, and the broader METAvivor team are currently finalizing the 2024 advocacy agenda, which focuses on increasing federal funding for the Metastatic Breast Cancer Access to Care Act—a bill designed to waive the waiting period for Social Security Disability Insurance (SSDI) and Medicare for those with a terminal MBC diagnosis.
Implications: The Future of Personalized Advocacy
The implications of Dr. Shanahan’s update are twofold: one medical and one social.
Medical Implications: The Rise of the "Village"
Dr. Shanahan’s reference to her "village of oncologists" highlights a growing trend in Stage IV care: the multidisciplinary team. Treatment is no longer a straight line; it is a constant recalibration. For the MBC community, the implication is clear: patients must be their own best advocates, pushing for repeat biopsies and genomic sequencing whenever the disease progresses. The upcoming Biomarker Education Program is a direct response to this need, aiming to empower patients with the vocabulary and knowledge to demand personalized care.
Social and Advocacy Implications
The shift in METAvivor’s focus toward the R.I.S.E initiative and peer-to-peer support indicates an acknowledgment of the mental health toll of MBC. As treatments improve and patients live longer with the disease, the "chronic" nature of Stage IV cancer requires sustained emotional and social infrastructure.
Furthermore, the "Stage IV Stampede" serves as a reminder that legislative change is as crucial as medical research. By bringing patients directly to the doors of Congress, METAvivor is ensuring that the "terminal" nature of the disease is not ignored by policymakers.
As Dr. Shanahan awaits her August scans, her message remains one of cautious optimism and relentless action. The upcoming "Light Up MBC" event on October 13 will serve as a global beacon of this mission—reminding the world that while the summer may be ending, the fight for the lives of the 168,000 Americans currently living with MBC is only intensifying.
About METAvivor:
METAvivor Research and Support is a non-profit organization dedicated to providing support for people living with metastatic breast cancer (MBC) and raising awareness and funds for MBC research. 100% of all donations and fundraiser proceeds go toward MBC research grants. For more information or to register for the Stage IV Stampede, visit metavivor.org.
About the Author
